Below is a list of links related to vaccines, and updated regularly:
Below is a list of articles related to vaccines, and updated regularly:
Ten Doesschate T, et al. "Efficacy of Bacillus Calmette-Guerin vaccination against respiratory tract infections in the elderly during the Covid-19 pandemic." Clin Infect Dis. 2022 Mar 5. https://doi.org/10.1093/cid/ciac182.
Shi Y, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis." Front Public Health. 2022 Apr 14;10:829176. https://doi.org/10.3389/fpubh.2022.829176. eCollection 2022.
Ramaiah V, et al. "Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India." Lancet. 2022 Apr 2;399(10332):1313-1321. https://doi.org/10.1016/S0140-6736(22)00151-9. (Original study)
Wang YP, et al. "SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis." J Chin Med Assoc. 2022 Apr 1;85(4):421-430. https://doi.org/10.1097/JCMA.0000000000000682.
Bansal V, et al. "Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression." Aliment Pharmacol Ther. 2022 Mar 30. https://doi.org/10.1111/apt.16913.
Roel E, et al. "Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis." BMJ. 2022 Mar 16;376:e068373. https://doi.org/10.1136/bmj-2021-068373.
Liu Q, et al. "Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Mar 10;10(3). https://doi.org/10.3390/vaccines10030421.
Alunno A, et al. "EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update." Ann Rheum Dis. 2022 Feb 23. https://doi.org/10.1136/annrheumdis-2021-222006.
Abu-Raddad LJ, et al. "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression." Lancet. 2022 Feb 21. https://doi.org/10.1016/S0140-6736(22)00152-0.
Wang Y, et al. "Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study." Lancet Reg Health West Pac. 2022 Apr;21:100393. https://doi.org/10.1016/j.lanwpc.2022.100393. Epub 2022 Feb 2.
Bouzas MB, et al. "Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials." Lancet Reg Health Am. 2022 May;9:100196. https://doi.org/10.1016/j.lana.2022.100196. Epub 2022 Feb 2.
McConeghy K, et al. "Evaluating the Findings of the IMPACT-C Randomized Clinical Trial to Improve COVID-19 Vaccine Coverage in Skilled Nursing Facilities." JAMA Intern Med. 2022 Jan 31. https://doi.org/10.1001/jamainternmed.2021.8067.
Guo X, et al. "Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial." Nat Med. 2022 Feb;28(2):401-409. https://doi.org/10.1038/s41591-021-01677-z. Epub 2022 Jan 27.
Veroniki AA, et al. "Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials." PLoS One. 2022 Jan 21;17(1):e0260733. https://doi.org/10.1371/journal.pone.0260733. eCollection 2022.
Clemens R, et al. "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study." Lancet. 2022 Jan 21. https://doi.org/10.1016/S0140-6736(22)00094-0.
Tran TM, et al. "Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine." Biomed Pharmacother. 2022 Jan 19;147:112650. https://doi.org/10.1016/j.biopha.2022.112650.
Tobudic S, et al. "Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial." Ann Rheum Dis. 2022 Jan 13. https://doi.org/10.1136/annrheumdis-2021-221558.
Veiga-Gutierrez R, et al. "Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial." Nutrients. 2022 Jan 5;14(1). https://doi.org/10.3390/nu14010228.
Eyre D, et al. "Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants." NEJM January 5, 2022 https://doi.org/10.1056/NEJMoa2116597.
Alunno A, et al. "Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations." Ann Rheum Dis. 2021 Dec 7. https://doi.org/10.1136/annrheumdis-2021-221575.
Neoh ZCF, et al. "Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis." Blood Adv. 2022 Apr 12;6(7):2014-2034. https://doi.org/10.1182/bloodadvances.2021006333.
Cornelius V, et al. "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial." Lancet. 2021 Dec 2. https://doi.org/10.1016/S0140-6736(21)02717-3.
Ongarj J, et al. "Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population." Vaccines (Basel). 2021 Nov 23;9(12). https://doi.org/10.3390/vaccines9121375.
Cosgrove C, et al. "Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial." Lancet Respir Med. 2021 Nov 17. https://doi.org/10.1016/S2213-2600(21)00409-4.
Tartour E, et al. "Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review." Clin Microbiol Infect. 2021 Oct 28. https://doi.org/10.1016/j.cmi.2021.09.036.
Noorchashm H, et al. "Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis." Cureus. 2021 Oct 28;13(10):e19102. https://doi.org/10.7759/cureus.19102. eCollection 2021 Oct.
Kulper-Schiek W, et al. "Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021." Euro Surveill. 2021 Oct;26(41). 14 Oct 2021 https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920.
Tian YC, et al. "Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis." JAMA Netw Open. 2021 Oct 1;4(10):e2131749. https://doi.org/10.1001/jamanetworkopen.2021.31749.
Shen Q, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review." Vaccines (Basel). 2021 Sep 29;9(10). https://doi.org/10.3390/vaccines9101102.
Yeung WWY, et al. "Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong." Ann Rheum Dis. 2021 Oct 22. https://doi.org/10.1136/annrheumdis-2021-221571.
As part of K2P COVID-19 Series, K2P center is pleased to launchA Closer Look at COVID-19 Vaccines: The Known, the Unknown, and the Uncertain
This is the second product on the COVID-19 Vaccine developed by K2P. To know more about the first product, you can check at: Countdown to a COVID-19 Vaccine: Spotlight on Lebanon